NewsHK
The global branded obesity-medication market grew volumes by roughly 70% from the second quarter of 2025, a demand environment that carried Novo Nordisk A/S through a margin-pressured quarter and into an upgraded full-year forecast.
The Danish drugmaker reported second-quarter adjusted sales of DKK 78.5 billion, up 7% at constant exchange rates, as GLP-1 volume gains across its obesity and diabetes franchises offset lower realized prices and a DKK 3 billion one-time manufacturing-capacity charge.
Oral Wegovy captures 90% of a new U.S.
market segment Six months after launching in the United States, the oral formulation of Wegovy crossed 5 million total prescriptions and was running at 267,000 weekly prescriptions as of July 17, according to Jamey Millar, executive vice president of U.S.
Keep reading